The etiologic role of human papillomavirus in penile cancers: a study in Vietnam

H T T Do¹, C Koriyama*¹, N A Khan¹, M Higashi², T Kato¹, N T Le³, S Matsushita⁴, T Kanekura⁴ and S Akiba¹

¹Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; ²Department of Human Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; ³Department of Occupational Health, Hanoi Medical University, 1st Ton That Tung street, Hanoi, Vietnam and ⁴Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan

Background: We investigated the aetiologic role of human papillomavirus (HPV) in 120 penile squamous cell carcinomas (PSCCs) from Vietnam.

Methods: Human papillomavirus DNA was detected by PCR using SPF10 primers and a primer set targeting HPV-16 E6. The INNO-LiPA HPV genotyping kit was used to determine genotype. Human papillomavirus-16 viral load and physical status were determined by real-time PCR. P16⁰INK⁴A protein expression was investigated by immunohistochemistry.

Results: Human papillomavirus DNA was detected in 27 of 120 (23%) PSCCs. The most frequently detected genotype was HPV-16 (24 of 27 cases, 89%). In 16 of 18 (89%) HPV-16-positive cases, the HPV DNA was considered to be integrated into the host genome. The geometric mean of the HPV-16 viral load was 0.4 copies per cell. P16⁰INK⁴A overexpression was significantly related to PSCCs infected with high-risk HPV (P = 0.018) and HPV-16 copy numbers (P < 0.001).

Conclusion: Human papillomavirus-16 DNA integration and p16⁰INK⁴A overexpression in high-risk HPV detected PSCCs suggested an aetiologic role of high-risk HPV in the development of PSCCs.

Penile cancer development is a multi-factorial process involving poor genital hygiene, phimosis, human papillomavirus (HPV), chronic inflammatory and premalignant conditions, and smoking (Misra et al., 2004). According to a systematic review, human papillomavirus (HPV) DNA was detected in 48%, on average, of penile squamous cell carcinomas (PSCCs) and the most frequent HPV-related histotype (66%) was basaloïd PSCC (Backes et al., 2009).

The integration of high-risk HPV genome into the host genome is suspected to be an important event for malignant transformation and cancer progression (Wentzensen et al., 2004; Williams et al., 2011). It usually disrupts the E2 gene, a suppressor of the E6/E7 promoter, leading to the overexpression of viral oncoproteins E6 and E7. The high viral load, frequently observed in cervical cancer, is also a determinant of cancer development (Wu et al., 2006).

The overexpression of p16⁰INK⁴A is a useful biomarker for evaluating the aetiologic role of HPV because HPV-E7 disturbs the p16⁰INK⁴A/cyclin D/Rb pathway, leading to the accumulation of p16⁰INK⁴A (Narisawa-Saito and Kiyono, 2007). In PSCC, however, the association between p16⁰INK⁴A overexpression and HPV presence is still unestablished (Ferreux et al., 2003; Poetsch et al., 2011; Stankiewicz et al., 2011a).

To understand the aetiologic role of HPV in the development of PSCCs, we examined the presence, genotype, viral load and physical status of high-risk HPV, and p16⁰INK⁴A expression in PSCCs in Vietnam.

MATERIALS AND METHODS

Study subjects. One hundred twenty paraffin-embedded PSCC specimens diagnosed at the National Cancer Hospital (Hanoi, Vietnam) between 2005 and 2010 were examined. Seventeen
cervical cancer specimens obtained at the same hospital during the same period were used as positive controls as HPV is a necessary cause of cervical cancers (zur Hausen, 2002). Histological subtypes were confirmed according to the World Health Organization histological classification of PSCCs (Cubilla et al, 2004). On the basis of TNM classification (Pizzocaro et al, 2010), clinical stage was divided into four stages by one of the authors (HD). This study was approved by the Institutional Review Board of Kagoshima University Graduate School of Medical and Dental Sciences.

**Human papillomavirus detection and genotyping.** Extracted DNAs from tissue specimens were checked for their qualities and the absence of PCR inhibitors by PCR for β-globin (Khan et al, 2008). Human papillomavirus DNA was detected by PCR using SPF10-biotinylated primers and a HPV-16-E6-specific primer set (Khan et al, 2008). Human papillomavirus typing was performed using the INNO-LiPA HPV Genotyping Extra test (Innogenetics, Ghent, Belgium) (Kleter et al, 1999), which can identify 28 genotypes: HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -68, -73, -82, -26, -53, -66, -6, -11, -40, -43, -44, -54, -70, -69, -71 and -74.

**Quantitative real-time PCR.** To examine the viral load and the physical status of HPV-16, all HPV-16-positive samples were subjected to quantitative real-time PCR with the ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) and 2x QuantTect SYBR Green PCR kit (Qiagen, Hilden, Germany). Details of the procedure were reported in the previous study.

### Table 1. Frequencies of HPV-positive cases by clinicopathological characteristics

| Clinicopathological characteristics | All N (%) | HPV-negative N (%) | HPV-positive N (%) | P-value* |
|-----------------------------------|-----------|--------------------|--------------------|---------|
| Number of cases                   | 120 (100) | 93 (77)            | 27 (23)            |         |
| Mean age at diagnosis (95% CI)    | 53 (51, 57)| 54 (51, 57)        | 51 (47, 55)        | 0.277   |

**Age at diagnosis (years)**

| Age at diagnosis (years) | HPV-negative N (%) | HPV-positive N (%) | P-value |
|--------------------------|--------------------|--------------------|---------|
| ≤45                      | 32 (24, 40)        | 8 (25)             | 0.273   |
| 46–55                    | 47 (35, 59)        | 12 (26)            |         |
| 56–65                    | 17 (12, 22)        | 5 (29)             |         |
| 66 and above             | 24 (19, 29)        | 2 (8)              |         |

**Histological subtype**

| Histological subtype | HPV-negative N (%) | HPV-positive N (%) | P-value |
|----------------------|--------------------|--------------------|---------|
| Basaloid             | 3 (3)              | 2 (67)             | 0.354   |
| Keratinising (usual type)* | 83 (64, 77)    | 19 (23)            |         |
| Non-keratinising     | 20 (17, 23)        | 3 (15)             |         |
| Verrucous            | 8 (6, 10)          | 2 (25)             |         |
| Warty(condylomatous) | 2 (1, 3)           | 0 (0)              |         |
| Undeterminedd         | 4 (3)              | 1 (25)             |         |

**Histological grade**

| Histological grade | HPV-negative N (%) | HPV-positive N (%) | P-value* |
|--------------------|--------------------|--------------------|---------|
| 1                  | 61 (52, 65)        | 9 (15)             | P for trend = 0.120* |
| 2                  | 36 (27, 46)        | 11 (20)            |         |
| 3                  | 19 (13, 25)        | 6 (32)             |         |
| Undeterminedd       | 4 (3)              | 1 (25)             |         |

**Stage**

| Stage | HPV-negative N (%) | HPV-positive N (%) | P-value* |
|-------|--------------------|--------------------|---------|
| 1     | 1 (1)              | 0 (0)              | P for trend = 0.815* |
| 2     | 29 (22, 36)        | 7 (24)             |         |
| 3     | 23 (16, 30)        | 7 (30)             |         |
| 4     | 6 (4, 8)           | 0 (0)              |         |
| Unknown | 61 (48, 74)    | 13 (21)            |         |

**Phimosis history**

| Phimosis history | HPV-negative N (%) | HPV-positive N (%) | P-value |
|------------------|--------------------|--------------------|---------|
| No               | 11 (10, 11)        | 1 (9)              | 0.433   |
| Yes              | 54 (40, 68)        | 14 (26)            |         |
| Unknown          | 55 (43, 67)        | 12 (22)            |         |

**Anatomic localisation**

| Anatomic localisation | HPV-negative N (%) | HPV-positive N (%) | P-value |
|-----------------------|--------------------|--------------------|---------|
| Penile glans          | 59 (46, 72)        | 13 (22)            | 0.180   |
| Penile preputium      | 3 (3)              | 2 (67)             |         |
| Both glans and preputium | 4 (3)            | 1 (25)             |         |
| Unspecified/unknown   | 54 (43, 65)        | 11 (20)            |         |

**Smoking history**

| Smoking history | HPV-negative N (%) | HPV-positive N (%) | P-value |
|-----------------|--------------------|--------------------|---------|
| No              | 44 (35, 53)        | 9 (20)             | 1.00    |
| Yes             | 12 (10, 14)        | 2 (17)             |         |
| Unknown          | 64 (48, 75)        | 16 (25)            |         |

Abbreviations: CI = confidence interval; HPV = human papillomavirus.

*aP*-values for heterogeneity, except unknown/undetermined cases, were obtained by Fisher's exact test.

*bP*-value was obtained by Student's *t*-test.

*cOne case with mixed keratinising-verrucous was included.

*dHistological subtype was undetermined in four cases due to tissue shortage.

*eP*-value was obtained by Cochran–Armitage trend test.
The physical status of the HPV-16 was determined by the HPV-16 E2/E6 ratio (Peitsaro et al., 2002). A lack of E2 amplification (E2/E6 ratio = 0) represents HPV-16 DNA integration into the host genome. When the E2/E6 ratio was equal to or higher than unity (E2/E6 ratio ≥ 1), the HPV-16 genome was considered as an episomal form, and the rest (0 < E2/E6 ratio < 1) was considered as a mixed form (mixture of episomal and integrated forms).

**Immunohistochemistry for p16INK4A.** The immunohistochemistry was conducted, using the mouse monoclonal antibody against p16INK4A (1:150 dilutions, 551153, BD Pharmingen, Tokyo, Japan). Details of the procedure were reported in the previous study (Baba et al., 2010). The p16INK4A expression was classified into the following four groups: <10%, 10–49%, 50–89% and ≥90%. The cases with ≥10% carcinoma cells stained positively were classified as positive.

## RESULTS

The β-globin was detected in all samples, indicating that DNA was available for molecular analysis. Twenty-seven of 120 (23%) PSCCs, including two of three (67%) basaloid PSCCs, were HPV positive (Table 1). Twenty-three HPV-positive cases were detected by SPF10 primers, and additional four cases by a HPV-16-specific primer set (PC-1, PC-4, PC-7 and PC-8 in Supplementary Table 1). The HPV prevalence did not differ by any clinicopathological parameters. In cervical carcinomas, HPV DNA was detected in 94% (16 out of 17) cases.

Human papillomavirus-16 was detected in 24 of 27 PSCCs. Other HPV genotypes detected included HPV-18, -11, -33 and -58 in one case each. Two cases had multiple infections: HPV-16/-58 and HPV-16/-18 (Supplementary Table 1). Human papillomavirus-16 E6 DNA was quantified in 18 of 24 HPV-16-positive PSCCs (Supplementary Table 1). The geometric means of E6 copies per cell were 0.4 in PSCCs and 3.0 in cervical cancers. Human papillomavirus DNA was in the integrated form in seven (39%), the mixed form in nine (50%) and the episomal form in two (11%) cases. In 13 HPV-16-positive cervical cancers, HPV integrated, mixed and episomal forms were found in four (31%), three (23%) and six (46%) cases, respectively.

Eighteen of 25 high-risk HPV (16 HPV-16, one HPV-16/-58 and one HPV-33)-positive cases and 26 randomly selected HPV-negative PSCCs were subjected to immunohistochemistry. Seven high-risk HPV-positive cases (PC-4, PC-5, PC-11, PC-14, PC-16, PC-17 and PC-22) were not examined due to tissue shortage.

Although p16INK4A had both nuclear and cytoplasmic immunoreactivity (Figure 1A and D), samples showing cytoplasmic immunoreactivity alone (Figure 1B and E) were not regarded as positive because the functionally activated p16INK4A was translocated into the nucleus. P16INK4A was expressed in 10 of 44 (23%) PSCCs (Supplementary Table 2). Human papillomavirus-positive PSCCs tended to show a frequent p16INK4A nuclear expression (Supplementary Table 2, P = 0.018). Strong p16INK4A nuclear expression was more frequently observed in HPV-16-positive PSCCs with a viral load ≥1 than those with a viral load <1 and HPV-negative PSCCs (Table 2, P for trend <0.001). Although all basaloid and non-keratinising types had high viral loads, 83% of the keratinising type harboured low viral loads (Table 2, P = 0.032). P16INK4A expression was not related to other factors, including tumour grade or stage (Supplementary Table 2).

## DISCUSSION

In the present study, p16INK4A overexpression was frequently observed in high-risk HPV-positive PSCCs, which is consistent with the findings in cervical cancers (Hwang and Shroyer 2012) and some studies of PSCCs (Ferreux et al., 2003; Stankiewicz et al., 2011a). Regarding HPV-negative PSCCs, p16INK4A expression was frequently suppressed by p16INK4A gene mutation or promoter hypermethylation (Poetsch et al., 2011). However, three HPV-negative PSCCs also showed p16INK4A overexpression (Table 2), which might occur independently of HPV infection such as mutational inactivation of pRB (Marur et al., 2010). A high viral load of HPV-16 was also related to strong p16INK4A nuclear
The first study reporting this association. P16INK4A overexpression per cell showed p16INK4A overexpression. To our knowledge, this is the first study reporting this association. P16INK4A overexpression may predict HPV transcription activity as reported in tonsillar cancer (Hoffmann et al., 2010).

The median HPV-16 viral loads (ranges) were 60.1255 (10.7–1239) and 0.0355 (0.002–0.322) copies per cell in the high (≥1 per cell) and low (<1 per cell) viral load groups, respectively. These ranges were similar to those in HPV-16 E6 mRNA-positive and -negative PSCCs, respectively (Heideman et al., 2007). Thus, approximately one copy per cell is a reasonable threshold to distinguish the viral transcription activity.

Relatively low viral loads in PSCCs might be due to the frequent HPV-16 integration because the viral load decreases after viral integration into the host genome (Berumen et al., 1995). The high frequency (89%) of HPV-16 integration in Vietnamese PSCCs (both integrated and mixed forms) is consistent with the findings by Tornesello et al. (1997) and Kalantari et al. (2008). Human papillomavirus integration, a marker of HPV-induced neoplasia, is not always found in cervical cancers (Cullen et al., 1991; Vernon et al., 1997). The discrepancy in HPV-16 integration rate between PSCCs and cervical cancers in the current study could be explained by the difference in tumour histological grades or aggressiveness, as HPV integration frequently occurs in a severe dysplastic lesion and invasive cervical carcinomas (Wentzensen et al., 2004). However, our sample size was too small to explore this hypothesis: only two PSCCs were in episomal form.

Demographic features and genetic backgrounds may contribute to the geographical difference of HPV prevalence in PSCCs worldwide. To date, there is no study reporting the HPV presence in PSCC in Vietnam. Although the HPV prevalence in Vietnamese PSCCs was relatively lower than the world average, a high frequency (94%) of HPV in cervical cancers indicated the appropriateness of our HPV DNA detection procedure.

Human papillomavirus presence was not significantly related to other PSCC risk factors including phimosis and smoking. Although clinical information was not obtained from nearly half of the study subjects, the HPV prevalence in these cases (20–25%) differed little from that of the entire group (23%). Thus, our negative finding was unlikely caused by biased information.

| Clinicopathological characteristics | HPV negative | Low (<1) N (%) | High (≥1) N (%) | P-value* |
|-----------------------------------|-------------|---------------|---------------|---------|
| Histological subtype              |             |               |               |         |
| Basaloid                          | 1 (1)       | 0 (0)         | 2 (33)        | 0.032   |
| Keratinising (usual type)         | 64 (69)     | 10 (83)       | 2 (33)        |         |
| Non-keratinising                  | 17 (18)     | 0 (0)         | 2 (33)        |         |
| Verrucous                         | 6 (6)       | 1 (8)         | 0 (0)         |         |
| Warty (condylomatous)             | 2 (2)       | 0 (0)         | 0 (0)         |         |
| Undetermined                      | 3 (3)       | 1 (8)         | 0 (0)         |         |
| Total                             | 93 (100)    | 13 (100)      | 6 (100)       |         |
| p16INK4A expression level         |             |               |               | P-for trend <0.001b |
| <10%                              | 23 (88)     | 8 (89)        | 0 (0)         |         |
| 10–49%                            | 3 (12)      | 1 (11)        | 0 (0)         |         |
| 50–89%                            | 0 (0)       | 0 (0)         | 3 (100)       |         |
| ≥90%                              | 0 (0)       | 0 (0)         | 0 (0)         |         |
| Total                             | 26 (100)    | 9 (100)       | 3 (100)       |         |

Table 2. Association of HPV-16 viral load with histological subtype and p16INK4A expression

Abbreviation: HPV – human papillomavirus.
*P-values for heterogeneity, except unknown/undetermined cases, were obtained by Fisher's exact test.
bP for trend was obtained by linear-by-linear association test.
26 HPV-negative samples were randomly selected from all HPV-negative samples.

CONCLUSION

The aetiologic role of high-risk HPV in the development of PSCCs was suggested by its DNA integration into the PSCC genome and its association with p16INK4A overexpression. P16INK4A could be a biomarker for HPV-related PSCCs.

ACKNOWLEDGEMENTS

This work was supported by Grants-in-Aids for Scientific Research on Priority Areas (17015037) of the Ministry of Education, Culture, Sports, Science and Technology, Japan. We would like to express our gratefulness to Dr Ta Van To, Department of Cytology and Pathology, National Cancer Hospital, 43 Quan Su, Hanoi, Vietnam, for kindly giving paraffin block specimens. We thank Joint Research Laboratory, Kagoshima University Graduate School of Medical and Dental Sciences, for the use of their facilities. We also thank Ms Junko Habu for her technical assistance.

REFERENCES

Baba M, Castillo A, Koriyama C, Yanagi M, Matsumoto H, Natsugoe S, Shuyama KY, Khan N, Higashi M, Hoh T, Eizuru Y, Aikou T, Akiba S (2010) Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas. Oncol Rep 23(4): 1085–1092.
Backes DM, Kurman RJ, Pimenta JM, Smith JS (2009) Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 20: 449–457.
Berumen J, Unger ER, Casas L, Figueroa P (1995) Amplification of human papillomavirus types 16 and 18 in invasive cervical cancer. Hum Pathol 26: 676–681.
Cubilla AL, Dillner J, Schellhammer PF, Horensblas S (2004) Tumours of the penis: malignant epithelial tumours. In Eble JN, Sauter G, Epstein JL, Sesterhenn I (eds) Chap 5. World Health Organization Classification of Tumours Pathology & Genetics of Tumours of the Urinary System and Male Genital Organs. pp 281–290. IARC: Lyon.
Cullen AP, Reid R, Campion M, Lőrinza AT (1991) Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 65: 606–612.

Ferreux E, Lont AP, Horenblas S, Gallee MP, Raaphorst FM, von Knebel Doeberitz M, Meijer CJ, Snijders PJ (2003) Evidence for at least three alternative mechanisms for the p16INK4a/cyclinD/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Pathol 201: 109–118.

Heideman DA, Waterboer T, Delis-van Diemen P, Nindl I, Leijte JA, Bonfrer JM, Horenblas S, Meijer CJ, Snijders PJ (2007) Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol 25: 4550–4556.

Hoffmann M, Ihloff AS, Görogh T, Weise JB, Fazel A, Krams M, Rittgen W, Schwarz E, Kahn T (2010) P16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer 127: 1595–1602.

Hwang SJ, Shroyer KR (2012) Biomarkers of cervical dysplasia and carcinoma. J Oncol 2012: doi:10.1155/2012/507286.

Kalantari M, Villa LL, Calejo-Macias IE, Bernard HU (2008) Human papillomavirus-16 and -18 in penile carcinomas: DNA methylation, chromosomal recombination and genomic variation. Int J Cancer 123: 1832–1840.

Khan NA, Castillo A, Koriyama C, Kijima Y, Umekita Y, Ohi Y, Higashi M, Sagara Y, Yoshinaka H, Tsuji T, Natsugoe S, Douchi T, Eizuru Y, Akiba S (2008) Human papillomavirus detected in female breast carcinomas in Japan. Br J Cancer 99: 408–414.

Kleter B, Van Doorn LJ, Schrauwen L, Moliijn A, Sastrowijoto S, ter Schegget J, Lindeman J, terHarmsel B, Burger M, Quint W (1999) Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37: 2508–2517.

Marur S, D’Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11(8): 781–789.

Misra S, Chaturvedi A, Misra NC (2004) Penile carcinoma: a challenge for the developing world. Lancet Oncol 5: 240–247.

Narisa-Saito P, Kiyono T (2007) Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci 98: 1505–1511.

Peitsaro P, Johansson B, Syrjanen S (2002) Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40: 886–891.

Pizzocaro G, Algaba F, Horenblas S, Solsona E, Tana S, Van Der Poel H, Watkin NA (2010) EAU Penile cancer guidelines 2009. Eur Urol 57: 1002–1012.

Poetsch M, Hemmerich M, Kakies C, Kleist B, Wolf E, vom Dorf F, Hakenberg OW, Protzel C (2011) Alterations in the tumor suppressor gene p16(INK4A) are associated with aggressive behavior of penile carcinomas. Virchows Arch 458(2): 221–229.

Supplementary Information accompanies this paper on British Journal of Cancer website (https://www.nature.com/bjc)